# Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

> **NCT02169609** · PHASE2 · COMPLETED · sponsor: **Fundació Sant Joan de Déu** · enrollment: 24 (actual)

## Conditions studied

- Neuroblastoma
- Neoplasm, Residual
- Effects of Immunotherapy

## Interventions

- **DRUG:** Dinutuximab. Immunotherapy

## Key facts

- **NCT ID:** NCT02169609
- **Lead sponsor:** Fundació Sant Joan de Déu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-26
- **Primary completion:** 2016-12-26
- **Final completion:** 2018-12-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169609, "Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02169609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*